Miacalcic®

Salmon Calcitonin Injection

Miacalcic® (Salmon Calcitonin Injection) was originally researched and developed by Novartis Pharma in Switzerland. 

Its mechanism of action involves inhibition of the biological activity of osteoclasts, reduction of the number of osteoclasts, prevention of bone loss, and improvement of bone mass. 

Additionally, it exhibits dual analgesic effects, making it frequently prescribed for the treatment of various indications related to osteoporosis, osteoporotic pain, and prevention of acute bone loss. 

【Indications】

• Prevention of sudden immobilization-induced acute bone loss, e.g., patients with recent osteoporotic fractures.

To prevent progressive bone loss, ensure intake of calcium and vitamin D according to individual needs during treatment.

• Paget's disease of bone (osteitis deformans) 

only in patients who do not respond to alternative treatments or for whom such treatments are not suitable.

• Hypercalcemia and hypercalcemic crisis 

 Tumoral osteolysis secondary to breast, lung or kidney carcinoma, myeloma and other 

malignancies. Hyperparathyroidism, immobilization, or vitamin D intoxication.

• Neurodystrophic disorders (synonymous with algodystrophy or Sudeck's disease) 

caused by various etiological and predisposing factors such as post-traumatic painful osteoporosis, reflex dystrophy, shoulder-arm syndrome, causalgia, drug-induced neurotrophic disorders..

【Specifications】1ml: 50IU

【Descriptions】Clear, colorless solution

【Dosage and Administration】

50-100 IU daily, injected subcutaneously or intramuscularly, depending on indications.

Detailed prescription information available upon request